Cagilintide (5mg & 10mg)

Cagilintide is a long-acting amylin receptor agonist analog, synthesized and lyophilized in the USA under controlled manufacturing conditions. Every production run is purified by high-performance liquid chromatography and identity-verified by mass spectrometry, achieving HPLC-MS purity above 99% with independent third-party batch certificates. Intended for laboratory research use only.

Studies of Cagilintide (5mg & 10mg) typically combine purity verification with functional assays to support reproducible results.

Researchers evaluating Cagilintide (5mg & 10mg) document batch COA data and storage conditions as part of experimental design.

Cagilintide (5mg & 10mg) is often included in comparative panels alongside related peptides to characterize research utility.

This product is available in 5mg and 10mg. Each vial contains lyophilized peptide at the labeled quantity; wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Cagilintide (5mg & 10mg). Summaries are provided for orientation only and reflect the cited sources.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial^[1] — This randomised, controlled phase 1b trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of the amylin analogue cagrilintide administered together with semaglutide 2.4 mg for weight management. The authors examined dose escalation and the interaction of the two agents across these measures. The results suggested that combined administration was generally well tolerated, supporting further study of this combination strategy. (Lancet (London, England) 2021)

Development of Cagrilintide, a Long-Acting Amylin Analogue^[2] — This study describes the design and development of cagrilintide as a long-acting acylated analogue of the pancreatic hormone amylin. The authors detail how structure-based modification and acylation were used to prolong its action while preserving amylin-like pharmacology. The work provides a foundation for the use of cagrilintide as a weight-management agent. (Journal of medicinal chemistry 2021)

Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs^[3] — This review discusses amylin-based pharmacotherapy as an approach to complement GLP-1-based treatments in weight management. The authors examine agents such as cagrilintide and their potential to improve the efficacy and tolerability of obesity pharmacotherapy. They consider the mechanistic rationale and clinical outlook for amylin analogues in this space. (Pharmacological research 2026)

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo^[4] — This meta-analysis evaluated the effects of cagrilintide and the cagrilintide-semaglutide combination (CagriSema) compared with placebo for obesity. The authors pooled data across eligible studies to estimate effects on weight-related outcomes. The findings suggested that both cagrilintide and CagriSema may provide weight-lowering benefits in adults with obesity. (Annals of medicine and surgery (2012) 2026)

References

1. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial." Lancet (London, England). 2021. pubmed.ncbi.nlm.nih.gov/33894838/
2. Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Johansson E, Fulle S, Skyggebjerg RB, Raun K. "Development of Cagrilintide, a Long-Acting Amylin Analogue." Journal of medicinal chemistry. 2021. pubmed.ncbi.nlm.nih.gov/34288673/
3. Fischer SL, Borner T. "Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs." Pharmacological research. 2026. pubmed.ncbi.nlm.nih.gov/42586227/
4. Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M. "Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo." Annals of medicine and surgery (2012). 2026. pubmed.ncbi.nlm.nih.gov/42583410/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.